NuCana plc ADR

Company Overview

Business Model: NuCana plc is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer medicines, called ProTides, by applying proprietary phosphoramidate chemistry to transform existing nucleoside analogs. This technology aims to overcome limitations of conventional chemotherapy agents, such as breakdown, poor uptake, and inefficient metabolic activation, to generate higher intracellular concentrations of active anti-cancer metabolites in cancer cells, thereby improving efficacy and safety. The company's pipeline includes NUC-7738 and NUC-3373, both in clinical development for various cancer indications.

Market Position: NuCana plc operates in the highly competitive biopharmaceutical industry, specifically targeting the global chemotherapy market, which is projected to reach approximately $106 billion by 2030. The company leverages its proprietary ProTide technology, which has a well-validated medicinal chemistry approach, to address the shortcomings of widely used nucleoside analogs. This technology is based on phosphoramidate chemistry, similar to that used in several FDA-approved antiviral drugs. NuCana plc owns or has exclusive rights to foundational patent estates for the application of this chemistry in oncology, with granted patents in key markets including the United States, Europe, China, and Japan.

Recent Strategic Developments:

• NUC-7738 Development: Initiated an expansion of the Phase 2 part of the NuTide:701 trial in June 2025, evaluating NUC-7738 in combination with pembrolizumab for metastatic melanoma. The company anticipates seeking regulatory guidance from the FDA in 2026 regarding a potential registrational pathway for NUC-7738 in melanoma.
• NUC-3373 Development: Completed the Phase 1b/2 modular NuTide:303 clinical trial in 2025, evaluating NUC-3373 in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer. The company is currently evaluating optimal combinations and indications for potential further clinical trials of NUC-3373 and expects to announce its development plan in 2026.
• Acelarin Program: Discontinued the Phase 3 NuTide:121 clinical trial in March 2022, investigating Acelarin in combination with cisplatin for biliary tract cancer, following a pre-planned futility analysis. Future development options for Acelarin in biliary tract cancer and other indications are being assessed.
• Capital Raising: Entered into an ATM sales agreement in June 2025, allowing for the periodic sale of ADSs up to an aggregate offering price of $100.0 million.
• ADS Ratio Change: Effected an ADS ratio change in August 2025, from one ADS representing twenty-five ordinary shares, to one ADS representing five thousand ordinary shares, to regain compliance with Nasdaq minimum bid price requirements.

Geographic Footprint: NuCana plc is incorporated in England and Wales and domiciled in the United Kingdom, with its principal executive offices in Edinburgh, United Kingdom. The company has a U.S. subsidiary, NuCana, Inc., and an Irish subsidiary, NuCana Limited. Clinical trials and sourcing of active pharmaceutical ingredients, raw materials, and services are conducted worldwide, including from the United States, the European Union, and India.

Cross-Border Operations:

• Subsidiaries: NuCana, Inc. (United States - Biotechnology Research and Development), NuCana Limited (Ireland - Biotechnology Research and Development), NuCana BioMed Trustee Company Limited (Scotland - Employee Benefit Trust).
• Licensing Agreements: Exclusive worldwide license with Cardiff University and Cardiff Consultants for certain nucleoside families of selected ProTides. Assignment, license, and collaboration agreement with Cardiff ProTides Ltd. for patents related to certain compounds, including Acelarin, and an exclusive worldwide license for unpatented compounds.
• Manufacturing & Clinical Trials: Relies on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) globally for preclinical studies and clinical trials, ensuring compliance with cGMP and GCP regulations across multiple jurisdictions.
• Regulatory Compliance: Seeks regulatory approval in multiple jurisdictions, including the United States (FDA) and the European Union (EMA), and is subject to varying regulatory requirements for drug development, marketing, pricing, and distribution.
• Currency Management: Maintains cash balances in U.S. dollars and other currencies to minimize exposure to exchange rate fluctuations, particularly between the pound sterling and the U.S. dollar.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 0% (No product sales)
• Operating Margin: -100% (No revenue)
• Net Margin: -100% (No revenue)

Investment in Growth:

• R&D Expenditure: £12.7 million (decreased from £18.0 million in 2024)
• Capital Expenditures: £0.02 million (Property, plant and equipment additions)
• Strategic Investments: Not explicitly detailed as separate line items, but R&D expenditure is the primary investment in growth.

Currency Impact Analysis:

• Foreign exchange impact on revenue and earnings: Net foreign exchange loss of £0.1 million in 2025, compared to a gain of £0.2 million in 2024. The 2025 loss primarily reflected the depreciation of the U.S. dollar against the U.K. pound sterling.
• Hedging strategies and effectiveness: NuCana plc does not use derivative instruments to manage exchange rate exposure. It seeks to minimize exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in various currencies, including U.S. dollars.
• Functional currency considerations: The company's functional currency is U.K. pounds sterling. Transactions in foreign currencies are recorded at spot rates, and monetary assets/liabilities in foreign currencies are translated at reporting date spot rates, with differences recognized in the consolidated statements of operations.

Business Segment Analysis

NuCana plc operates in one operating segment: the business of developing and commercializing ProTides for use in Oncology. Therefore, a detailed subsection for each major segment with revenue, growth, and operational metrics is not applicable.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries:
  • NuCana, Inc.: United States - Biotechnology Research and Development
  • NuCana Limited: Ireland - Biotechnology Research and Development
  • NuCana BioMed Trustee Company Limited: Scotland - Employee Benefit Trust
• Joint Ventures: Not explicitly mentioned in the filing.
• Licensing Agreements:
  • Cardiff University and Cardiff Consultants: Exclusive worldwide license for nucleoside families of selected ProTides.
  • Cardiff ProTides Ltd.: Exclusive worldwide license for certain unpatented compounds and assigned patents related to compounds including Acelarin.

Cross-Border Trade:

• Export Markets: Not applicable as no products are commercialized.
• Import Dependencies: Sources active pharmaceutical ingredients, raw materials, research and development, manufacturing, consulting, and other services worldwide, including from the United States, the European Union, and India.
• Transfer Pricing: Not explicitly detailed in the filing, but subject to challenge by tax authorities.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not mentioned in the filing.
• Dividend Payments: NuCana plc has never declared or paid a dividend and does not anticipate doing so in the foreseeable future, intending to retain earnings for business development and growth.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None mentioned.

Balance Sheet Position:

• Cash and Equivalents: £24.3 million (as of December 31, 2025)
• Total Debt: Not explicitly detailed as traditional debt. Lease liabilities are £0.68 million (current £0.02 million, non-current £0.66 million).
• Net Cash Position: £24.3 million (considering cash and equivalents against lease liabilities)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Lease liabilities maturity: £0.07 million (less than 1 year), £0.18 million (1-3 years), £0.19 million (3-5 years), £0.56 million (later than 5 years).

Cash Flow Generation:

• Operating Cash Flow: (£7.5 million) (used in operating activities for 2025)
• Free Cash Flow: Not explicitly calculated, but negative given operating cash flow and capital expenditures.
• Cash Conversion Metrics: Not explicitly detailed.

Currency Management:

• Cash holdings by major currencies: A significant portion of cash and cash equivalents is held in U.S. dollars.
• Natural hedging through operational diversification: Not explicitly stated, but the company's global sourcing and potential future international revenue streams could provide some natural hedging.
• Financial hedging instruments and strategies: NuCana plc does not use derivative instruments to manage exchange rate exposure.

Operational Excellence

Production & Service Model: NuCana plc does not own or operate manufacturing facilities. It relies on third-party contract manufacturing organizations (CMOs) for the supply of clinical trial materials for NUC-7738 and NUC-3373, and any future product candidates, under current good manufacturing practice (cGMP) standards. The company also relies on medical institutions, clinical investigators, contract laboratories, and contract research organizations (CROs) to conduct or support its clinical trials.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Active Pharmaceutical Ingredient (API) & Raw Materials: Sourced from third parties worldwide, including the United States, the European Union, and India.
• Manufacturing Partners: Third-party CMOs for clinical trial materials and expected for commercial manufacture, ensuring cGMP compliance.
• Clinical Trial Partners: Medical institutions, clinical investigators, contract laboratories, and CROs for conducting and supporting clinical trials.
• Technology Partners: Cardiff University and Cardiff ProTides Ltd. for intellectual property and research collaboration.

Facility Network:

• Manufacturing: Relies on third-party CMOs globally.
• Research & Development: Conducted internally and through collaborations with third parties (e.g., Cardiff University, Cardiff ProTides Ltd.).
• Distribution: Not yet established, as no products are approved for commercial sale.
• Executive Office: Edinburgh, United Kingdom (3,900 sq ft, lease expiry August 14, 2037).

Operational Metrics: Not explicitly disclosed in a consolidated format beyond R&D expenditure.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Plans to commercialize any approved product candidates in major markets like the United States and Europe using a specialized sales force, either independently or in partnership.
• Channel Partners: May enter into partnerships with commercialization partners.
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Enterprise Customers: Not applicable as no products are commercialized. Strategic Partnerships: Not applicable as no products are commercialized. Customer Concentration: Not applicable as no products are commercialized.

Regional Market Penetration: Not applicable as no products are commercialized.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry, particularly in oncology, is highly competitive, capital-intensive, and characterized by lengthy, expensive, and uncertain drug development processes. The global chemotherapy market is projected to reach approximately $106 billion by 2030. Key competitive factors include efficacy, safety profile, price, convenience of administration, and promotional activity. The market is influenced by major pharmaceutical, biotechnology, and specialty pharmaceutical companies, as well as academic institutions and research organizations.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Major Pharmaceutical and Biotechnology Companies: Companies that market and sell products or are developing products for cancer treatment, including existing chemotherapies, immunotherapies, and targeted drug therapies.
• Generic Pharmaceutical Manufacturers: Companies producing off-patent chemotherapies like 5-FU and gemcitabine, which are substantially less expensive.
• Other Companies using Phosphoramidate Chemistry: Potential competition from other companies developing cancer therapies using similar scientific approaches.

Regional Competitive Dynamics: Competition varies by region, with different regulatory approval processes, pricing controls, and reimbursement policies impacting market entry and commercial success. Many competitors have significantly greater financial resources and expertise in all stages of drug development and commercialization.

Risk Assessment Framework

Strategic & Market Risks

• Global Market Dynamics: Economic weakness (inflation), political instability, differing regulatory requirements, reduced intellectual property protection, changes in currency exchange rates, trade protection measures, differing reimbursement regimes, negative tax law changes, geopolitical conflicts (Ukraine, Middle East), and public health crises (pandemics) could adversely affect business.
• Technology Disruption: High failure rate in drug development, preliminary clinical data may not be indicative of final results, and inability to successfully expand the ProTide technology platform to build new product candidates.
• Customer Concentration: Not applicable as no products are commercialized.

Operational & Execution Risks

• Global Supply Chain Vulnerabilities: Heavy reliance on third-party CROs and CMOs for clinical trials and manufacturing, increasing risks of insufficient quantities, unacceptable costs, quality issues, and non-compliance with cGMP/GCP. Single-source suppliers for key materials pose a risk of supply interruption.
• Regional Disruptions: Geopolitical actions, natural disasters, and public health emergencies can disrupt clinical trials, supply chains, and regulatory processes.
• Trade Restrictions: Export controls, tariffs, and trade barriers could impact international operations.
• Internal Systems: Vulnerability of internal computer systems and those of third-party contractors to cybersecurity incidents, potentially leading to data loss, operational disruption, and legal liabilities.
• Employee Matters: Limited number of employees, dependence on key executives, and challenges in attracting and retaining qualified personnel.
• Managing Growth: Difficulties in managing anticipated development and expansion, including implementing managerial, operational, and financial systems, and recruiting/training personnel.

Financial & Regulatory Risks

• Currency & Financial Risks: Exchange rate fluctuations (especially GBP vs. USD) can adversely affect results. Inadequate funding, potential going concern issues, and adverse developments in the financial services industry could impair operations.
• Interest Rate Risk: Exposure to interest rate sensitivity on cash and cash equivalents.
• Credit & Liquidity: Majority of cash and cash equivalents held at A-rated financial institutions, but above FSCS protection limits.
• Regulatory & Compliance Risks: Extensive and evolving regulation by FDA, EMA, and other authorities. Potential for undesirable side effects delaying or preventing approval, extensive post-marketing requirements, and compliance with anti-kickback, fraud and abuse, and privacy laws (GDPR, U.K. GDPR, CCPA, My Health My Data Act, EHDS Regulation).
• Tax Regulations: Uncertainty regarding net operating loss and tax credit carryforwards, potential changes in U.K. R&D tax credit regimes, and disagreements with tax authorities on tax positions (e.g., transfer pricing).
• Product Liability: Inherent risk of product liability exposure from clinical trials and commercial sales.

Geopolitical & External Risks

• Country-Specific Risks: Economic, political, and regulatory risks associated with international operations, including potential Scottish independence referendum and divergence in U.K. and E.U. laws.
• Economic Risk: Unstable market and economic conditions (inflation, interest rates) could adversely affect business and stock price.
• Regulatory Changes: Future legislation (e.g., ACA, IRA, PBM reforms in the U.S., E.U. pharmaceutical legislation revisions) could increase costs, delay approvals, or affect pricing and reimbursement.

Innovation & Technology Leadership

Research & Development Focus: NuCana plc's R&D focuses on applying its proprietary ProTide technology to transform nucleoside analogs into more effective and safer anti-cancer medicines. This involves designing ProTides to overcome limitations of nucleoside analogs, such as breakdown, poor uptake, and inefficient metabolic activation, to achieve higher intracellular concentrations of active anti-cancer metabolites. The company is developing NUC-7738 (disrupts RNA polyadenylation, impacts gene expression, targets TME) and NUC-3373 (targeted Thymidylate Synthase inhibitor, enhances TS inhibition, improves tolerability).

Global R&D Network:

• R&D Centers: Not explicitly detailed as separate physical centers, but R&D activities are conducted internally and through collaborations with academic institutions (e.g., Cardiff University) and CROs globally.
• Innovation Pipeline: Focus on NUC-7738 (Phase 2 for metastatic melanoma, potential registrational pathway in 2026) and NUC-3373 (evaluating optimal combinations and indications for further clinical trials in 2026). Also pursuing transformation of additional nucleoside analogs.

Intellectual Property Portfolio:

• Patent Strategy: Actively seeks to obtain and maintain patents in key markets (U.S., Europe, China, Japan) covering composition of matter, formulations, manufacturing methods, and specific uses of its product candidates. Relies on data exclusivity, market exclusivity, and patent term extensions where available.
• Patent Holdings: As of February 24, 2026, owns 284 granted patents (26 U.S. issued) and 61 pending patent applications (5 U.S. pending).
  • NUC-7738: 85 granted patents and 6 pending applications, expected to expire in 2035 (composition of matter) and 2036, 2038, 2043 (formulations, methods, uses).
  • NUC-3373: 87 granted patents, expected to expire in 2032 (composition of matter). Patents for clinical formulation granted in U.S. and Japan, expected to expire in 2036, 2037, 2038, 2043.
  • Acelarin: 10 granted patents and 1 pending application for single diastereoisomer form, expected to expire in 2033.
• Licensing Programs: Has license agreements with Cardiff University and Cardiff ProTides Ltd. for foundational intellectual property.
• IP Litigation: Recognizes the risk of costly and time-consuming litigation to enforce or defend patent rights.

Technology Partnerships: Collaborations with Cardiff University and Cardiff ProTides Ltd. for discovery, drug design, and in vitro screening.

Leadership & Governance

Executive Leadership Team

International Management Structure:

• Regional leadership and reporting relationships are not explicitly detailed, but the executive team has global experience.
• Local management autonomy and centralized oversight are not explicitly detailed.

Board Composition:

• Composed of five members: Hugh Griffith (Executive Director), Andrew Kay (Non-Executive Director and Chairman), Martin Mellish (Non-Executive Director), Cyrille Leperlier, M.D. (Non-Executive Director), and Elliott Levy, M.D. (Non-Executive Director).
• Independence: Martin Mellish, Cyrille Leperlier, M.D., and Elliott Levy, M.D. are considered independent directors as defined by Nasdaq rules. Hugh Griffith and Andrew Kay are not independent.
• International Expertise: Directors possess extensive experience in the biopharmaceutical industry, global drug development, marketing, and finance across various regions.
• Regulatory Compliance: The company follows Nasdaq corporate governance rules applicable to foreign private issuers, which permits reliance on home country practices in lieu of certain Nasdaq standards.
• Committee Structure: Includes an Audit Committee (Martin Mellish, Cyrille Leperlier), a Remuneration Committee (Andrew Kay, Elliott Levy), and a Nominating and Governance Committee (Hugh Griffith, Andrew Kay). The Development Committee ceased to exist in December 2025, with its duties assumed by the board.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework:

• Primary Regulatory Environments:
  • United States: Subject to extensive regulation by the FDA under the FD&C Act, including preclinical testing (GLP), IND submission, clinical trials (GCP), NDA submission, and post-marketing requirements (cGMP, adverse event reporting, promotion/advertising restrictions, REMS). Also subject to federal and state healthcare fraud and abuse laws (Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act).
  • European Union: Subject to EMA approval via Marketing Authorization Application (MAA) procedures (centralized, mutual recognition). Clinical trials governed by the Clinical Trials Regulation (Regulation (E.U.) 536/2014). New Directive and Regulation revising pharmaceutical legislation finalized in December 2025, with phased implementation between 2027 and 2031.
  • United Kingdom: Subject to MHRA regulations. U.K. medicines legislation has not materially deviated from E.U. law post-Brexit, but the MHRA has an International Recognition Procedure for expedited U.K. marketing authorization based on decisions from "Reference Regulators" (e.g., FDA, EMA).
• Cross-Border Compliance:
  • Export Controls: Subject to U.S. and U.K. export control regulations.
  • Sanctions Compliance: Subject to economic sanctions and embargoes on certain countries and persons.
  • Anti-Corruption: Subject to the U.K. Bribery Act 2010, U.S. Foreign Corrupt Practices Act (FCPA), and U.K. Criminal Finances Act 2017 (CFA 2017) regarding facilitation of tax evasion.
  • Data Privacy: Subject to GDPR (E.U.), U.K. GDPR, and various U.S. state laws (CCPA, CPRA, My Health My Data Act, Nevada SB 370, Connecticut amendments) for personal data protection, including health information. The EHDS Regulation (E.U.) entered into force in March 2025, with phased implementation from 2027-2031, creating additional compliance burdens for health data.
• International Tax Strategy:
  • Transfer Pricing: Subject to challenge by tax authorities regarding allocation of income by tax jurisdiction and intercompany arrangements.
  • Tax Treaties: Not explicitly detailed.
  • BEPS Compliance: Not explicitly detailed.

Environmental & Social Impact

Global Sustainability Strategy: Not explicitly detailed in the filing.

Environmental Commitments: Not explicitly detailed in the filing.

Regional Sustainability Initiatives: Not explicitly detailed in the filing.

Social Impact by Region: Not explicitly detailed in the filing.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies:

• Transaction Hedging: Not explicitly stated, but the company seeks to minimize exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in various currencies.
• Translation Hedging: Not explicitly stated.
• Economic Hedging: Not explicitly stated.
• Financial Hedging Instruments: NuCana plc does not use derivative instruments to manage exchange rate exposure.